Literature DB >> 9448046

Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung.

A Hancock1, L Armstrong, R Gama, A Millar.   

Abstract

Human interleukin 13 (IL-13) is a cytokine that has a profound effect on primary immune cells by inducing immunoglobulin production, proliferation of B cells, and the differentiation of cells of the monocytic lineage. IL-13 can inhibit the production of inflammatory cytokines by both macrophages and monocytes. Previously, IL-13 expression has been reported only in cells of the T-cell lineage and the mast cell line HMC-1. We now report the presence of IL-13 mRNA and protein in human alveolar macrophages (AMs) analyzed by the reverse transcription-polymerase chain reaction (RT-PCR) and enzyme-linked immunoabsorbent assay (ELISA), respectively, and IL-13 protein in bronchoalveolar lavage fluid (BALF) of subjects with pulmonary fibrosis. We have investigated 13 patients from 49 to 75 yr of age with forms of pulmonary fibrosis, and eight healthy volunteers from 24 to 61 yr of age. Their AMs were obtained by bronchoalveolar lavage (BAL) and purified by adherence. The proportion of BAL purified AMs expressing IL-13 mRNA was increased in those subjects with fibrotic lung disease, in comparison with those from control subjects (11 of 13 versus 2 of 8, P < 0.01). IL-13 protein was detectable in the BALF of 8 of 13 patients with pulmonary fibrosis, but in none of the control subjects. AMs of four subjects with systemic sclerosis were cultured and IL-13 protein was increased in the culture supernatants when compared to the control subjects, although this did not reach significance. These findings show that IL-13 mRNA is not only a product of T cells, but is also expressed in both normal AMs and those from subjects with pulmonary fibrosis, and that at least some of the IL-13 mRNA is translated into protein and secreted in subjects with pulmonary fibrosis. We hypothesize that IL-13 may be expressed by normal human AMs as part of the homeostatic control process but its production may be increased in the presence of inflammatory lung disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9448046     DOI: 10.1165/ajrcmb.18.1.2627

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  88 in total

Review 1.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Repetitive intradermal bleomycin injections evoke T-helper cell 2 cytokine-driven pulmonary fibrosis.

Authors:  Brijendra Singh; Rajesh K Kasam; Vishwaraj Sontake; Thomas A Wynn; Satish K Madala
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2017-08-03       Impact factor: 5.464

4.  Modulation of lung inflammation by the Epstein-Barr virus protein Zta.

Authors:  James F Guenther; Jennifer E Cameron; Hong T Nguyen; Yu Wang; Deborah E Sullivan; Bin Shan; Joseph A Lasky; Erik K Flemington; Gilbert F Morris
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2010-09-03       Impact factor: 5.464

5.  Role of TNFR1 in lung injury and altered lung function induced by the model sulfur mustard vesicant, 2-chloroethyl ethyl sulfide.

Authors:  Vasanthi R Sunil; Kinal Patel-Vayas; Jianliang Shen; Andrew J Gow; Jeffrey D Laskin; Debra L Laskin
Journal:  Toxicol Appl Pharmacol       Date:  2010-11-09       Impact factor: 4.219

6.  ERK1/2 mitogen-activated protein kinase selectively mediates IL-13-induced lung inflammation and remodeling in vivo.

Authors:  Patty J Lee; Xuchen Zhang; Peiying Shan; Bing Ma; Chun Geun Lee; Robert J Homer; Zhou Zhu; Mercedes Rincon; Brooke T Mossman; Jack A Elias
Journal:  J Clin Invest       Date:  2005-12-22       Impact factor: 14.808

Review 7.  Transgenic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling.

Authors:  Chun Geun Lee; Hye-Ryun Kang; Robert J Homer; Geoffrey Chupp; Jack A Elias
Journal:  Proc Am Thorac Soc       Date:  2006-07

8.  Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model.

Authors:  Lynne A Murray; Huilan Zhang; Sameer R Oak; Ana Lucia Coelho; Athula Herath; Kevin R Flaherty; Joyce Lee; Matt Bell; Darryl A Knight; Fernando J Martinez; Matthew A Sleeman; Erica L Herzog; Cory M Hogaboam
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

Review 9.  Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.

Authors:  Karen Au; Dinesh Khanna; Philip J Clements; Daniel E Furst; Donald P Tashkin
Journal:  Curr Rheumatol Rep       Date:  2009-04       Impact factor: 4.592

10.  Pulmonary infection with an interferon-gamma-producing Cryptococcus neoformans strain results in classical macrophage activation and protection.

Authors:  Sarah E Hardison; Sailatha Ravi; Karen L Wozniak; Mattie L Young; Michal A Olszewski; Floyd L Wormley
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.